{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T09:22:08Z","timestamp":1787995328515,"version":"build-2784847793"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T00:00:00Z","timestamp":1670889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Extramedullary plasmacytoma (EMP) is a localized plasma cell neoplasm that originates from tissues other than bone. The survival trends and prognostic factors of patients with EMP in recent years remain unreported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We used the SEER databases to extract the data. Survival curves were calculated using the Kaplan-Meier method and a nomogram was created based on the Cox\u2019s proportional hazards model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 1676 cases of EMP were identified. Patients in period-2 (2008-2016) show similar survival (p=0.8624) to those in period-1(1975-2007). Age, gender, race, and sites were prognostic of patient outcomes. And the use of surgery was associated with improved survival. The patients were randomly assigned to the training cohort and the validation cohort in a ratio of 2:1. Four factors including age, gender, race, and sites were identified to be independently predictive of the overall survival of patients with EMP. A prognostic model (EMP prognostic index, EMP-PI) comprising these four factors was constructed. Within the training cohort, three risk groups displayed significantly different 10-year survival rates: low-risk (73.0%, [95%CI 66.9-78.2]), intermediate-risk (39.3%, [95%CI 34.3-44.3]), and high-risk (22.6%, [95%CI 15.3-30.9]) (p&amp;lt;0.0001). Three risk groups were confirmed in the internal validation cohort. We also constructed a 5-factor nomogram based on multivariate logistic analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The survival of patients with EMP did not improve in recent years. The EMP-PI will facilitate the risk stratification and guide the risk-adapted therapy in patients with EMP.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.1052903","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T05:53:00Z","timestamp":1670910780000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Survival trends and prognostic factors for patients with extramedullary plasmacytoma: A population-based study"],"prefix":"10.3389","volume":"12","author":[{"given":"Xuxing","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Run","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-8140(99)00114-0","article-title":"Clinical course of solitary extramedullary plasmacytoma","volume":"52","author":"Liebross","year":"1999","journal-title":"Radiother Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.01.004","article-title":"Overall survival trends and clinical characteristics of plasmacytoma in the united states: A national cancer database analysis","volume":"19","author":"Ghiassi-Nejad","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13045-017-0549-1","article-title":"Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European expert panel","volume":"11","author":"Caers","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.11.037","article-title":"Multi-institutional analysis of solitary extramedullary plasmacytoma of the head and neck treated with curative radiotherapy","volume":"82","author":"Sasaki","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2005.06.039","article-title":"Outcomes and patterns of failure in solitary plasmacytoma: a multicenter rare cancer network study of 258 patients","volume":"64","author":"Ozsahin","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14291.","article-title":"Progression of a solitary plasmacytoma to multiple myeloma. a population-based registry of the northern Netherlands","volume":"175","author":"de Waal","year":"2016","journal-title":"Br J Haematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(00)01572-8","article-title":"Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome","volume":"50","author":"Tsang","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B8","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00405-017-4817-z","article-title":"Pattern of care and impact of prognostic factors on the outcome of head and neck extramedullary plasmacytoma: a systematic review and individual patient data analysis of 315 cases","volume":"275","author":"Venkatesulu","year":"2018","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2017.05.08","article-title":"Management of extramedullary plasmacytoma: Role of radiotherapy and prognostic factor analysis in 55 patients","volume":"29","author":"Wen","year":"2017","journal-title":"Chin J Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1186\/s12885-016-2824-x","article-title":"Establishment of an innovative staging system for extramedullary plasmacytoma","volume":"16","author":"Zhu","year":"2016","journal-title":"BMC Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13870","article-title":"Clinical features and prognostic factors in solitary plasmacytoma","volume":"172","author":"Finsinger","year":"2016","journal-title":"Br J Haematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/alr.21544","article-title":"Sinonasal extramedullary plasmacytoma: a population-based incidence and survival analysis","volume":"5","author":"Patel","year":"2015","journal-title":"Int Forum Allergy Rhinol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/0194599813481334","article-title":"Epidemiologic evidence of superior outcomes for extramedullary plasmacytoma of the head and neck","volume":"148","author":"Gerry","year":"2013","journal-title":"Otolaryngol Head Neck Surg"},{"key":"B14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1365-2141.2008.07421.x","article-title":"Plasmacytoma of bone, extramedullary plasmacytoma, and multiple myeloma: incidence and survival in the united states, 1992-2004","volume":"144","author":"Dores","year":"2009","journal-title":"Br J Haematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.3323","article-title":"Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the united states","volume":"31","author":"Warren","year":"2013","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016002493","article-title":"Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the united states","volume":"1","author":"Costa","year":"2017","journal-title":"Blood Adv"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3533","article-title":"Survival trends and prognostic factors in patients with solitary plasmacytoma of bone: A population-based study","volume":"10","author":"Shen","year":"2021","journal-title":"Cancer Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.827188","article-title":"Recent improvement in survival of patients with multiple myeloma: variation by ethnicity","volume":"55","author":"Pulte","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-019-00499-8","article-title":"Solitary plasmacytoma: a review of diagnosis and management","volume":"14","author":"Pham","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19990601)85:11<2305::AID-CNCR2>3.0.CO;2-3","article-title":"Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts","volume":"85","author":"Alexiou","year":"1999","journal-title":"Cancer"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30189-4.","article-title":"Role of (18)F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the international myeloma working group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1052903\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T05:53:02Z","timestamp":1670910782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1052903\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,13]]},"references-count":26,"alternative-id":["10.3389\/fonc.2022.1052903"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.1052903","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,13]]},"article-number":"1052903"}}